




Contents lists available at ScienceDirect

Auris Nasus Larynx

journal homepage: www.elsevier.com/locate/anl



Staging and classification criteria for middle ear cholesteatoma proposed by the Japan Otological Society[☆]

Tetsuya Tono^{a,*}, Masafumi Sakagami^b, Hiromi Kojima^c, Yutaka Yamamoto^c,
Keiji Matsuda^a, Manabu Komori^d, Naohito Hato^e, Yuka Morita^f, Sho Hashimoto^g

^a Department of Otolaryngology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

^b Department of Otolaryngology, Hyogo College of Medicine, Kobe, Japan

^c Department of Otolaryngology, Jikei University School of Medicine, Tokyo, Japan

^d Department of Otolaryngology, National Center for Child Health and Development, Tokyo, Japan

^e Department of Otolaryngology, Ehime University School of Medicine, Ehime, Japan

^f Department of Otolaryngology, Faculty of Medicine, Niigata University, Niigata, Japan

^g Department of Otolaryngology, National Sendai Medical Center, Sendai, Japan

ARTICLE INFO

Article history:

Received 27 May 2016

Accepted 28 June 2016

Available online xxx

Keywords:

Middle ear cholesteatoma

Classification

Staging

ABSTRACT

In order to provide a basis for meaningful exchange of information among those treating cholesteatoma, the Committee on Nomenclature of the Japan Otological Society (JOS) was appointed in 2004 to create a cholesteatoma staging system as simple as possible to use in clinical practice in Japan. Following the announcement of preliminary criteria for the staging of pars flaccida (attic) cholesteatoma in 2008, we proposed the 2010 JOS staging system for two major types of retraction pocket cholesteatoma, pars flaccida and pars tensa cholesteatoma. Since then, the JOS staging system has been widely used in clinical studies of cholesteatoma in Japan, allowing standardization in reporting of surgical outcomes based on the respective stages of cholesteatoma. We have recently expanded the range of cholesteatoma by adding cholesteatoma secondary to a tensa perforation and congenital cholesteatoma as the 2015 JOS staging system for middle ear cholesteatoma. Although further revisions may be required for universal acceptance of these criteria, we hope our staging system will open the way for international consensus on staging and classification of middle ear cholesteatoma in the near future.

© 2016 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Middle ear cholesteatoma is characterized by a mass lesion formed by keratinizing squamous epithelium, keratin debris and varying thickness of perimatrix, with or without surrounding inflammatory reaction. Because of the multifactorial and

progressive nature of the disease process, pathophysiological conditions vary considerably from case to case. Hence, the operating surgeon is required to make a subjective decision regarding the most appropriate surgical technique for the individual situation, to achieve optimal surgical goals, including disease eradication and subsequent functional and anatomical stabilization. Classification and staging of cholesteatoma would provide a standardized assembly of a relatively homogenous group of patients, allowing rational interpretation of surgical results based on respective pathophysiological conditions of the disease process. Needless to say, proper classification criteria can only be created

[☆] All authors belong to the Committee on Nomenclature of the Japan Otological Society (JOS). The criteria set has been approved by the JOS Board of Directors.

* Corresponding author.

E-mail address: tono@med.miyazaki-u.ac.jp (T. Tono).

<http://dx.doi.org/10.1016/j.anl.2016.06.012>

0385-8146/© 2016 Elsevier Ireland Ltd. All rights reserved.

by a consensus-based approach, preferably with the support of an academic society, and should undergo revision over time.

2. Impact of the previous proposal of criteria (the 2010 JOS staging system) on clinical studies of cholesteatoma in Japan

The Committee on Nomenclature of the Japan Otological Society (JOS) was appointed in 2004 to create a cholesteatoma staging system as simple as possible to use in clinical practice, in order to provide a basis for meaningful exchange of information among those treating cholesteatoma. Although several criteria for cholesteatoma classification/staging have been proposed worldwide [1–5], none of them are simple enough nor are they authorized by an academic society. Assuming that the tympanomastoid surgery based on the type of cholesteatoma has been discussed and cultivated differently in each country, it was hoped that a consensus-based staging system primarily for Japanese otolaryngologists could be developed to start with.

Following the announcement of preliminary criteria for the staging of pars flaccida (attic) cholesteatoma in 2008 [6], we proposed the 2010 JOS staging system [7] for two major types of retraction pocket cholesteatoma, pars flaccida and pars tensa cholesteatoma. The basic concept of this system was twofold: (1) The middle ear space was divided into four sites: protympanum (P), tympanic cavity (T), attic (A) and mastoid (M); (2) Three stages were defined: in stage I, the lesion is confined to the attic or the tympanic cavity; in stage II, the lesion extends beyond the attic or the tympanic cavity; in stage III, intratemporal and/or intracranial complications are observed. Stages II and III can be further sub-classified according to the extension of the cholesteatoma using the PTAM system. For example, if the matrix has invaded the protympanum, the attic and the mastoid antrum without causing any complications, it is described as “stage II PAM”.

Since then, the 2010 JOS staging system has been widely used in clinical studies of cholesteatoma in Japan, allowing standardization not only in reporting of surgical outcomes but also in clinical communications between physicians and patients based on the respective stage of cholesteatoma. The number of medical articles referring to the JOS system has gradually increased in Japanese literature during the past 7 years. A search of the key words of “cholesteatoma” AND “staging” in the Japan Medical Abstracts Society web site, produced 46 original papers and 60 conference abstracts between 2008 and 2015 [8].

3. Background of the current revision of the previous criteria

In 2012, we were given the opportunity to present the JOS staging system during the 9th International Conference on cholesteatoma and ear surgery in Nagasaki, Japan (Chairman of the meeting, Prof. Haruo Takahashi) [9]. In one of the panel discussions entitled “Panel with response analyzer to build up

international consensus on classification and staging of middle ear cholesteatoma (modulators: Prof. Nuri Ozgirgin and Prof. Naoaki Yanagihara)”, this system gained favourable responses from the international audience as judged by the results of the response analyzer. However, one point to be considered in order to make this staging system internationally acceptable was a suggestion to separate the intracranial complications from the stage III elements because intracranial complications are life-threatening complications which are of great concern worldwide.

Although the 2010 JOS staging system was designed exclusively for pars flaccida and pars tensa cholesteatomas, at least two entities unrelated to a retraction pocket in origin are fairly well recognized in Japan: cholesteatoma secondary to a chronic tensa perforation and congenital cholesteatoma. The former is cholesteatoma that develops secondary to ingrowth of squamous epithelium through a pre-existing tensa perforation (so-called secondary acquired cholesteatoma). Careful observation using a microscope or an endoscope is essential to discriminate a continuous epithelial invasion from the perforation edge to the underside of the pars tensa with no direct adhesive lesion to the promontorial mucosa [10]. Although a clear distinction between this type of cholesteatoma and pars tensa cholesteatoma may be difficult in some cases, the specific staging criteria described below would help better understanding of the characteristic process of this disease entity. The latter is congenital cholesteatoma that develops behind an intact tympanic membrane. Although academic studies abroad showed that the typical location of congenital cholesteatoma is in the anterior superior quadrant of the tympanic cavity [11,12], this is not necessarily true in Japan, where the posterior superior quadrant is reportedly the most common site [13,14]. Therefore, it would be worthwhile to survey clinical data of congenital cholesteatoma nationwide using the same staging criteria, specific for this project.

The current committee to improve the criteria was convened under the Japan Otological Society in 2014 to address these issues. The original Japanese version has already been published as the 2015 JOS staging system [15] and its English version is reported here following a public comment period of 2 months. The cholesteatoma classification has been slightly modified from the Japanese version through a collaborative dialogue with members of the cholesteatoma guidelines group of the European Academy of Otolaryngology and Neurotology.

4. Proposed new set of criteria: the 2015 JOS staging system for middle ear cholesteatoma

4.1. Classification of cholesteatoma

I. Acquired cholesteatoma

- 1) Retraction pocket cholesteatoma (so-called primary acquired cholesteatoma)
 - a) *Pars flaccida cholesteatoma (Attic cholesteatoma)*: Cholesteatoma originating in a pars flaccida retraction pocket.

Download English Version:

<https://daneshyari.com/en/article/8754975>

Download Persian Version:

<https://daneshyari.com/article/8754975>

[Daneshyari.com](https://daneshyari.com)